These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32140416)

  • 1. Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: Recommendations for distinct scenarios in Latin America.
    Solano M; Fainboim A; Politei J; Porras-Hurtado GL; Martins AM; Souza CFM; Koch FM; Amartino H; Satizábal JM; Horovitz DDG; Medeiros PFV; Honjo RS; Lourenço CM
    Mol Genet Metab Rep; 2020 Jun; 23():100572. PubMed ID: 32140416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.
    Solano VM; Mandujano CYC; Avila-Rejon CA; Espin VH; Montaño HPQ
    Mol Genet Metab Rep; 2021 Sep; 28():100769. PubMed ID: 34113545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
    Nan H; Park C; Maeng S
    Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical ocular manifestations of Taiwanese patients with mucopolysaccharidoses VI (Maroteaux-Lamy syndrome).
    Lin HY; Huang YH; Lei SY; Chen LJ; Lin SP
    Taiwan J Ophthalmol; 2019; 9(3):194-197. PubMed ID: 31572657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique medical issues in adult patients with mucopolysaccharidoses.
    Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K
    Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families.
    Coman DJ; Hayes IM; Collins V; Sahhar M; Wraith JE; Delatycki MB
    J Pediatr; 2008 May; 152(5):723-7. PubMed ID: 18410781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
    Kakkis E; Marsden D
    Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newborn screening and diagnosis of mucopolysaccharidoses.
    Tomatsu S; Fujii T; Fukushi M; Oguma T; Shimada T; Maeda M; Kida K; Shibata Y; Futatsumori H; Montaño AM; Mason RW; Yamaguchi S; Suzuki Y; Orii T
    Mol Genet Metab; 2013; 110(1-2):42-53. PubMed ID: 23860310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI.
    Lin HY; Chuang CK; Chen MR; Lin SM; Hung CL; Chang CY; Chiu PC; Tsai WH; Niu DM; Tsai FJ; Lin SJ; Hwu WL; Lin JL; Lin SP
    Mol Genet Metab; 2016 Apr; 117(4):431-7. PubMed ID: 26899310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy: efficacy and limitations.
    Concolino D; Deodato F; Parini R
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):120. PubMed ID: 30442189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.
    Pearse Y; Iacovino M
    Med Res Arch; 2020 Feb; 8(2):. PubMed ID: 32733997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional capacity evaluation of patients with mucopolysaccharidosis.
    Guarany NR; Schwartz IV; Guarany FC; Giugliani R
    J Pediatr Rehabil Med; 2012; 5(1):37-46. PubMed ID: 22543891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Craniovertebral junction pathological features and their management in the mucopolysaccharidoses.
    Sganzerla EP; Giussani C; Grimaldi M; Parini R; Ingelmo P; Trezza A; Visocchi M
    Adv Tech Stand Neurosurg; 2014; 40():313-31. PubMed ID: 24265052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
    Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
    Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The patients` perspective on home-based infusion: A longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy.
    Heinrich R; Claus F; Schoenfelder T
    Mol Genet Metab Rep; 2023 Jun; 35():100971. PubMed ID: 37065272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses.
    Safary A; Moghaddas-Sani H; Akbarzadeh-Khiavi M; Khabbazzi A; Rafi MA; Omidi Y
    Expert Opin Biol Ther; 2021 Sep; 21(9):1181-1197. PubMed ID: 33653197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucopolysaccharidoses in northern Brazil: Targeted mutation screening and urinary glycosaminoglycan excretion in patients undergoing enzyme replacement therapy.
    Viana GM; de Lima NO; Cavaleiro R; Alves E; Souza IC; Feio R; Leistner-Segal S; Schwartz I; Giugliani R; da Silva LC
    Genet Mol Biol; 2011 Jul; 34(3):410-5. PubMed ID: 21931511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The characterisation of pulmonary function in patients with mucopolysaccharidoses IVA: A longitudinal analysis.
    Kenth JJ; Thompson G; Fullwood C; Wilkinson S; Jones S; Bruce IA
    Mol Genet Metab Rep; 2019 Sep; 20():100487. PubMed ID: 31341787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.